Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 5/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.47 |
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
| ▸ | ATR | Q13535 | 14/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18985877 | 0.89 | CYP4F2 (0.50) | CYP4F2CYP4A11IDH1ATR | |
| SCHEMBL12079810 | 0.89 | CYP4F2 (0.50) | CYP4F2CYP4A11IDH1ATR | |
| SCHEMBL20641888 | 0.83 | CYP4F2 (0.46) | CYP4F2CYP4A11IDH1ATR | |
| SCHEMBL21724972 | 0.82 | CYP4F2 (0.50) | CYP4F2CYP4A11IDH1ATR | |
| SCHEMBL20641863 | 0.81 | CYP4F2 (0.42) | CYP4F2CYP4A11IDH1ATR | |
| SCHEMBL30437949 | 0.81 | CYP4F2 (0.42) | CYP4F2CYP4A11IDH1ATR | |
| SCHEMBL12079955 | 0.81 | ATR (0.48) | CYP4F2CYP4A11IDH1ATR | |
| SCHEMBL23649500 | 0.80 | CYP4F2 (0.49) | CYP4F2CYP4A11IDH1ATR | |
| SCHEMBL25300700 | 0.80 | CYP4F2 (0.52) | CYP4F2CYP4A11IDH1ATR | |
| SCHEMBL23154226 | 0.79 | ATR (0.49) | CYP4F2CYP4A11IDH1ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361237-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | ORIGENIS GMBH (DE) | 2025-11-27 | — | — | US | disclosed |
| US-12384788-B2 | 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as LRRK2, NUAK1 and/or TYK2 kinase modulators for the treatment of e.g. autoimmune disease | ORIGENIS GMBH (DE) | 2025-08-12 | — | — | US | disclosed |
| EP-4327884-A2 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASES | Origenis GmbH (DE) | 2024-02-28 | — | — | EP | disclosed |
| EP-4028017-B1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASES | ORIGENIS GMBH (DE) | 2023-12-06 | — | — | EP | disclosed |
| US-11827597-B2 | Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation | INNATE TUMOR IMMUNITY, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827597-B2 | Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation | INNATE TUMOR IMMUNITY, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827597-B2 | Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation | INNATE TUMOR IMMUNITY, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230097144-A1 | SUBSTITUTED 4-AMINO-1H-IMIDAZO[4,5-c]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION | INNATE TUMOR IMMUNITY INC (US) | 2023-03-30 | — | — | US | disclosed |
| US-20230097144-A1 | SUBSTITUTED 4-AMINO-1H-IMIDAZO[4,5-c]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION | INNATE TUMOR IMMUNITY INC (US) | 2023-03-30 | — | — | US | disclosed |
| US-11572360-B2 | Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation | INNATE TUMOR IMMUNITY, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-11572360-B2 | Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation | INNATE TUMOR IMMUNITY, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220380374-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | ORIGENIS GMBH (DE) | 2022-12-01 | — | — | US | disclosed |
| US-20220380373-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | ORIGENIS GMBH (DE) | 2022-12-01 | — | — | US | disclosed |
| EP-4028017-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | Origenis GmbH (DE) | 2022-07-20 | — | — | EP | disclosed |
| EP-4028016-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | Origenis GmbH (DE) | 2022-07-20 | — | — | EP | disclosed |
| US-20210332040-A1 | SUBSTITUTED 4-AMINO-1H-IMIDAZO[4,5-c]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION | INNATE TUMOR IMMUNITY INC (US) | 2021-10-28 | — | — | US | disclosed |
| US-20210332040-A1 | SUBSTITUTED 4-AMINO-1H-IMIDAZO[4,5-c]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION | INNATE TUMOR IMMUNITY INC (US) | 2021-10-28 | — | — | US | disclosed |
| WO-2021048620-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | ORIGENIS GMBH (DE) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021048618-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | ORIGENIS GMBH (DE) | 2021-03-18 | — | — | WO | disclosed |
| WO-2020037094-A1 | SUBSTITUED 4-AMINO-1H-IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION | INNATE TUMOR IMMUNITY, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230097144-A1 | SUBSTITUTED 4-AMINO-1H-IMIDAZO[4,5-c]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION | NLRP3, NOD1, NLRP1 | CYP4F2 1429/4885CYP4A11 338/4885IDH1 2204/4885 |
| US-12384788-B2 | 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as LRRK2, NUAK1 and/or TYK2 kinase modulators for the treatment of e.g. autoimmune disease | NUAK1, TYK2, MARK1 | CYP4F2 3348/4885CYP4A11 2952/4885IDH1 4190/4885 |
| US-20220380374-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | NUAK1, TYK2, MARK1 | CYP4F2 3338/4885CYP4A11 2947/4885IDH1 4195/4885 |
| US-20220380373-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | NUAK1, TYK2, MARK1 | CYP4F2 3348/4885CYP4A11 2952/4885IDH1 4190/4885 |
| US-11827597-B2 | Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation | NLRP3, NOD1, NLRP1 | CYP4F2 1429/4885CYP4A11 338/4885IDH1 2204/4885 |
| US-20250361237-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | NUAK1, TYK2, MARK1 | CYP4F2 3348/4885CYP4A11 2952/4885IDH1 4190/4885 |
| US-11572360-B2 | Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation | NLRP3, NOD1, NLRP1 | CYP4F2 1429/4885CYP4A11 338/4885IDH1 2204/4885 |
| US-20210332040-A1 | SUBSTITUTED 4-AMINO-1H-IMIDAZO[4,5-c]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION | NLRP3, NOD1, NLRP1 | CYP4F2 1429/4885CYP4A11 338/4885IDH1 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.